PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
No Data
No Data available this quarter, please select a different quarter.
3.04
Dangerously high net debt exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.98. Michael Burry would check for debt covenant compliance and refinancing risks.
-6.54
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
14.53
Current ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.35. Joel Greenblatt would verify if this conservative approach provides competitive advantages.
1.13%
Intangibles 50-90% of Drug Manufacturers - Specialty & Generic median of 1.64%. Charlie Munger would examine if industry dynamics justify more tangible-heavy model.